<DOC>
	<DOCNO>NCT02732639</DOCNO>
	<brief_summary>This study evaluate efficacy safety 48-week treatment pegylated interferon ( PEG-IFN ) alfa-2a ( Pegasys ) monotherapy participant chronic hepatitis D ( CHD ) . Treatment follow 24 week treatment-free follow-up .</brief_summary>
	<brief_title>A Study Pegylated Interferon ( PEG-IFN ) Alfa-2a ( Pegasys ) Participants With Chronic Hepatitis D ( CHD )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Positive hepatitis B surface antigen ( HBsAg ) least 6 month prior screen Positive antidelta least 3 month prior screen Positive hepatitis D virus ( HDV ) ribonucleic acid ( RNA ) A liver biopsy obtain within past 18 month noncirrhotic patient 30 month cirrhotic patient demonstrate liver disease consistent chronic hepatitis D ( CHD ) Negative urine serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose test drug Antiviral therapy CHD within previous 6 month Positive hepatitis A , hepatitis C , human immunodeficiency virus ( HIV ) Evidence decompensated liver disease Other medical condition associate chronic liver disease Women ongoing pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>